American Heart Journal
Volume 147, Issue 6 , Pages 966-976 , June 2004

Can change in high-density lipoprotein cholesterol levels reduce cardiovascular risk?

  • Bonnie B Dean, MPH, PhD

      Affiliations

    • Zynx Health, Inc, a Cerner Company, Beverly Hills, Calif, USA
    • ,
  • Jeff E Borenstein, MD, MPH

      Affiliations

    • Zynx Health, Inc, a Cerner Company, Beverly Hills, Calif, USA
    • Departments of Medicine and Health Services Research, Cedars-Sinai Health System and the UCLA School of Medicine, Los Angeles, Calif, USA
    • ,
  • James M Henning, MS

      Affiliations

    • TAP Pharmaceutical Products, Inc, Lake Forest, Ill, USA
    • ,
  • Kevin Knight, MD, MPH

      Affiliations

    • Zynx Health, Inc, a Cerner Company, Beverly Hills, Calif, USA
    • Corresponding Author InformationReprint requests: Kevin Knight, MD, MPH, Zynx Health Inc, 9100 Wilshire Blvd, Suite E655, Beverly Hills, CA 90212, USA.
    • ,
  • C.Noel Bairey Merz, MD, FACC

      Affiliations

    • Division of Cardiology, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, Calif, USA

Received 18 March 2003 ,Accepted 17 October 2003.

References 

  1. Castelli WP, Garrison RJ, Wilson PW, et al.  Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA. 1986;256:2835–2838
  2. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;256:2823–2828
  3. Wilson PW, Anderson KM, Castelli WP. Twelve-year incidence of coronary heart disease in middle-aged adults during the era of hypertensive therapy (the Framingham offspring study). Am J Med. 1991;90:11–16
  4. Frick MH, Elo O, Haapa K, et al.  Helsinki Heart Study (primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease). N Engl J Med. 1987;317:1237–1245
  5. Gordon DJ, Knoke J, Probstfield JL, et al.  High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men (the Lipid Research Clinics Coronary Primary Prevention Trial). Circulation. 1986;74:1217–1225
  6. Wilson PW, Abbott RD, Castelli WP. High-density lipoprotein cholesterol and mortality (the Framingham Heart Study). Arteriosclerosis. 1988;8:737–741
  7. Thompson GR, Hollyer J, Waters DD. Percentage change rather than plasma level of LDL-cholesterol determines therapeutic response in coronary heart disease. Curr Opin Lipidol. 1995;6:386–388
  8. Jukema JW, Bruschke AV, van Boven AJ, et al.  Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels (the Regression Growth Evaluation Statin Study (REGRESS)). Circulation. 1995;91:2528–2540
  9. Scandinavian Simvastatin Survival Study Group . Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet. 1995;345:1274–1275
  10. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998;97:1440–5
  11. Sacks FM, Gibson CM, Rosner B, et al.  The influence of pretreatment low density lipoprotein cholesterol concentrations on the effect of hypocholesterolemic therapy on coronary atherosclerosis in angiographic trials. Harvard Atherosclerosis Reversibility Project Research Group. Am J Cardiol. 1995;76:78–85C
  12. Shah PK, Kaul S, Nilsson J, et al.  Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins (an idea whose time for testing is coming, part I). Circulation. 2001;104:2376–2383
  13. Shah PK, Kaul S, Nilsson J, et al.  Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins (an idea whose time for testing is coming, part II). Circulation. 2001;104:2498–2502
  14. Robins SJ, Collins D, Wittes JT, et al.  Relation of gemfibrozil treatment and lipid levels with major coronary events (VA-HIT: a randomized controlled trial). JAMA. 2001;285:1585–1591
  15. Cheung MC, Zhao XQ, Chait A, et al.  Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL. Arterioscler Thromb Vasc Biol. 2001;21:1320–1326
  16. Brown BG, Zhao XQ, Chait A, et al.  Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583–1592
  17. Knuiman MW, Vu HT. Prediction of coronary heart disease mortality in Busselton, Western Australia (an evaluation of the Framingham, national health epidemiologic follow up study, and WHO ERICA risk scores). J Epidemiol Community Health. 1997;51:515–519
  18. Dobson AJ, Evans A, Ferrario M, et al.  Changes in estimated coronary risk in the 1980s (data from 38 populations in the WHO MONICA Project. World Health Organization. Monitoring trends and determinants in cardiovascular diseases). Ann Med. 1998;30:199–205
  19. Waters D, Higginson L, Gladstone P, et al.  Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation. 1994;89:959–968
  20. Brensike JF, Levy RI, Kelsey SF, et al.  Effects of therapy with cholestyramine on progression of coronary arteriosclerosis (results of the NHLBI Type II Coronary Intervention Study). Circulation. 1984;69:313–324
  21. Tamura A, Mikuriya Y, Nasu M. Effect of pravastatin (10 mg/day) on progression of coronary atherosclerosis in patients with serum total cholesterol levels from 160 to 220 mg/dl and angiographically documented coronary artery disease. Coronary Artery Regression Study (CARS) Group. Am J Cardiol. 1997;79:893–896
  22. Teo KK, Burton JR, Buller CE, et al.  Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis (the Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT)). Circulation. 2000;102:1748–1754
  23. von Schacky C, Angerer P, Kothny W, et al.  The effect of dietary omega-3 fatty acids on coronary atherosclerosis (a randomized, double-blind, placebo-controlled trial). Ann Intern Med. 1999;130:554–562
  24. Sacks FM, Pasternak RC, Gibson CM, et al.  Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group. Lancet. 1994;344:1182–1186
  25. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994;344:633–8
  26. Sacks FM, Stone PH, Gibson CM, et al.  Controlled trial of fish oil for regression of human coronary atherosclerosis. HARP Research group. J Am Coll Cardiol. 1995;25:1492–1498
  27. White HD, Simes RJ, Anderson NE, et al.  Pravastatin therapy and the risk of stroke. N Engl J Med. 2000;343:317–326
  28. Elkeles RS, Diamond JR, Poulter C, et al.  Cardiovascular outcomes in type 2 diabetes (a double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study). Diabetes Care. 1998;21:641–648
  29. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–9
  30. Herd JA, Ballantyne CM, Farmer JA, et al.  Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study. [LCAS]) Am J Cardiol. 1997;80:278–286
  31. Blankenhorn DH, Azen SP, Kramsch DM, et al.  Coronary angiographic changes with lovastatin therapy (the Monitored Atherosclerosis Regression Study (MARS). The MARS Research Group). Ann Intern Med. 1993;119:969–976
  32. Furberg CD, Adams HP, Applegate WB, et al.  Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research group. Circulation. 1994;90:1679–1687
  33. Mercuri M, Bond MG, Sirtori CR, et al.  Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population (the Carotid Atherosclerosis Italian Ultrasound Study). Am J Med. 1996;101:627–634
  34. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000;102:21–7
  35. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Am J Cardiol 1993;72:1031–7
  36. Pitt B, Mancini GB, Ellis SG, et al.  Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I) (reduction in atherosclerosis progression and clinical events. PLAC I investigation). J Am Coll Cardiol. 1995;26:1133–1139
  37. Singh RB, Niaz MA, Sharma JP, et al.  Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction (the Indian experiment of infarct survival-4). Cardiovasc Drugs Ther. 1997;11:485–491
  38. Byington RP, Furberg CD, Crouse JR, et al.  Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol. 1995;76:54–59C
  39. Gundersen T, Kjekshus J, Stokke O, et al.  Timolol maleate and HDL cholesterol after myocardial infarction. Eur Heart J. 1985;6:840–844
  40. Hulley S, Grady D, Bush T, et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) research group. JAMA. 1998;280:605–613
  41. Sacks FM, Pfeffer MA, Moye LA, et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001–1009
  42. Frick MH, Syvanne M, Nieminen MS, et al.  Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterolLopid Coronary Angiography Trial (LOCAT) Study group. Circulation. 1997;96:2137–2143
  43. Ericsson CG, Hamsten A, Nilsson J, et al.  Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet. 1996;347:849–853
  44. Brown G, Albers JJ, Fisher LD, et al.  Regression of coronary artery disease as a result of intensive lipid- lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289–1298
  45. Rubins HB, Robins SJ, Collins D, et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study group. N Engl J Med. 1999;341:410–418
  46. Bestehorn HP, Rensing UF, Roskamm H, et al.  The effect of simvastatin on progression of coronary artery disease. The Multicenter coronary Intervention Study (CIS). Eur Heart J. 1997;18:226–234
  47. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251:365–74
  48. Blankenhorn DH, Nessim SA, Johnson RL, et al.  Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233–3240
  49. Salonen R, Nyyssonen K, Porkkala E, et al.  Kuopio Atherosclerosis Prevention Study (KAPS) (a population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries). Circulation. 1995;92:1758–1764
  50. Shepherd J, Cobbe SM, Ford I, et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study group. N Engl J Med. 1995;333:1301–1307
  51. Downs JR, Clearfield M, Weis S, et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels (results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study). JAMA. 1998;279:1615–1622
  52. Liao Y, McGee DL, Cooper RS, et al.  How generalizable are coronary risk prediction models? Comparison of Framingham and two national cohorts. Am Heart J. 1999;137:837–845
  53. Ballantyne CM, Olsson AG, Cook TJ, et al.  Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation. 2001;104:3046–3051
  54. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486–97

PII: S0002-8703(04)00051-1

doi: 10.1016/j.ahj.2003.10.051

American Heart Journal
Volume 147, Issue 6 , Pages 966-976 , June 2004

Article Tools

* Image Usage & Resolution